Bemcentinib was the first AXL-specific inhibitor to enter clinical investigation and is currently in phase I/II clinical trials, either alone or in combination with other therapies, for the treatment of AML, myelodysplastic syndromes (MDS), triple-negative breast cancer (TNBC), glioblastoma, NSCLC, metastatic melanoma and malignant mesothelioma (NCT03965494, NCT02922777, NCT02872259, NCT03184558, NCT03184571, NCT02488408, NCT02424617, NCT03824080 and NCT03654833). Here, AXL is linked to acute myeloid leukemia.